Navigation Links
InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
Date:9/30/2009

carcinogenicity following lifetime exposure to INT131. These results are enabling for INT131 to initiate planned Phase 3 clinical studies.

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. INT131 has been designed to provide a safer therapeutic tool for physicians and patients, which is complementary to available classes of medications, and allows for powerful glucose control and the opportunity for modification of the underlying disease. As a SPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned to safely improve insulin resistance, addressing an important unmet medical need.

About InteKrin (www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

SOURCE InteKrin Therapeutics Inc.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... -- Instacare Corp. (OTC Bulletin Board: ISCR) a ... drugs and diagnostics and at home testing products ... and provider of e-health technologies and revolutionary cell ... as part of the preparation of its Fiscal ... two new Directors and has rejected, as unneeded, ...
(Date:12/17/2009)... Inc. (Nasdaq: ANDS ) today announced preliminary results from ... the first dose cohort, 200 mg bid, in an ongoing ... and ribavirin (SOC) in HCV patients. 56% of patients ... IU/ml) at week 4, known as R apid ... of patients receiving placebo plus SOC. ,, ANA598 ...
(Date:12/17/2009)... Resources, one of the world,s leading research and ... finds that over 70 percent of surveyed U.S. ... diabetes drugs with novel mechanisms of action versus ... need for additional DPP-IV inhibitors. Both surveyed physicians ... ability and physicians in particular say the most ...
Breaking Medicine Technology:Instacare Corp. Board of Directors Sets Growth Plans for 2010 2ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 2ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 3ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 4ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 5ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 6ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 7Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3GARP makes the difference 8832 1GARP makes the difference 8832 2Rice University researchers ask if biofuels will lead to a drink or drive 8827 1Rice University researchers ask if biofuels will lead to a drink or drive 8827 2Sinovac Completes Construction of H1N1 Virus Seed Bank 12626 1Sinovac Completes Construction of H1N1 Virus Seed Bank 12626 2Sinovac Completes Construction of H1N1 Virus Seed Bank 12626 3
... Describes ... Endothelial Disease, NEW ORLEANS, Nov. 12 In ... Annual Meeting, Massimo Busin,MD, department head and professor of ... technique that significantly improved,results in patients being treated for ...
... Inc. (Nasdaq: LXRX ) announced today that ... to the U.S. Food and Drug,Administration (FDA) for ... other autoimmune conditions. The initial Phase 1 clinical,trial ... ascending single-dose study in healthy volunteers,designed to evaluate ...
Other Medicine Technology:Improved Cornea Surgery Technique Provides Enhanced Transplant Success 2Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 2Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis 3
(Date:12/17/2009)... CareTech Solutions ( www.CareTech.com ), an information ... hospitals and health systems, was named Best in KLAS, ... 2009 Top 20 Best in KLAS Awards: Software & ... the performance of vendors in key market segments including ... ,, CareTech,s overall performance score was 90.3 on ...
(Date:12/17/2009)... -- AlloSource, one of the nation,s largest non-profit providers ... in surgical procedures and the world,s largest processor of ... has been selected as a finalist in the 2010 ... Samaritan Institute category honoring non-profits. This is the second ... as a finalist by the annual awards program, now ...
(Date:12/17/2009)... DIEGO (December 17, 2009) Researchers from the ... aim at several of the world,s most dangerous infectious ... a five-year, $18.8 million federally-funded set of projects seeking ... , The Institute received four project awards ... and Infectious Diseases (NIAID), part of the National Institutes ...
(Date:12/17/2009)... Personal Stories of Inspiration on How Exercise Has Helped, Healed, and ... ... 2009 -- The International Health, Racquet & Sportsclub Association (IHRSA) announced ... it is urging Americans of all ages and abilities to make ... a culture of movement in America wherein regular daily exercise is ...
(Date:12/17/2009)... Villanova University Is Taking Their Leading Master of Science in ... ... Tampa, Fla. (PRWEB) December 17, 2009 -- Open enrollment ... program , which is ideal for working professionals whose busy ... of Science in Human Resource Development debuting online in March ...
Breaking Medicine News(10 mins):Health News:CareTech Solutions Named 2009 'Best in KLAS' for Extensive Information Technology Outsourcing for the Second Consecutive Year 2Health News:CareTech Solutions Named 2009 'Best in KLAS' for Extensive Information Technology Outsourcing for the Second Consecutive Year 3Health News:AlloSource Recognized for Exemplifying Ethics Amongst Colorado Non-Profits 2Health News:AlloSource Recognized for Exemplifying Ethics Amongst Colorado Non-Profits 3Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 3Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 4Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 5Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 2Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 3Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 4Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 5Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3
... Healthy Building is the theme of this year,s conference;, learn ... in the field of electromagnetic radiation (EMR) and building science ... who are creating healthy buildings every day, NASHVILLE, Tenn., ... buildings but as a wellness professional have you ever,asked yourself, ...
... Children,s Fluoride Rinse, with Special Tinting Feature to Encourage Healthier ... ... March 11 Parents confess that kids,can be full of excuses, ... survey of parents with children ages six to 12,conducted by StrategyOne ...
... Physicians and,Nurses Against Tobacco, Inc., (PANAT) an ... petitioning Pope Benedict,XVI to condemn the production, distribution, ... of State, to declare the Vatican the first ... political, spiritual, and moral leader,to set an example ...
... in Dosimetry and Phase II Trials, with Some Patients Already Past the Expected ... Survival Time for This Population -, - Data From ... ... TUSTIN, Calif., March 11 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage ...
... - Unconscious prejudices among doctors may explain why women ... to be recommended for total knee replacement surgery, a ... Journal suggests. , Toronto researchers used two standardized ... with moderate knee osteoarthritis reporting the same symptoms of ...
... inhibitor letrozole (Femara) can reduce the risk of breast cancer ... course of tamoxifen therapy. The results of a study ... trial of letrozole will appear in the Journal of Clinical ... who chose to begin letrozole treatment after the initial trial ...
Other Medicine News:Health News:2008 Building Biology(R) Conference, April 19th & 20th, Hotel Radisson at Opryland, Nashville, Tennessee 2Health News:2008 Building Biology(R) Conference, April 19th & 20th, Hotel Radisson at Opryland, Nashville, Tennessee 3Health News:The Disappearing Toothbrush: Survey Reveals Kids' Top Excuses to Avoid Brushing 2Health News:The Disappearing Toothbrush: Survey Reveals Kids' Top Excuses to Avoid Brushing 3Health News:The Disappearing Toothbrush: Survey Reveals Kids' Top Excuses to Avoid Brushing 4Health News:Physicians and Nurses Against Tobacco (PANAT) Petition Pope Benedict XVI to Condemn Tobacco Industry, and Tobacco Use, and Declare Vatican First Tobacco- Free Country 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 3Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 4Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 5Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 6Health News:Gender bias may affect care of people with osteoarthritis, study finds 2Health News:Late treatment with letrozole can reduce breast cancer recurrence risk 2Health News:Late treatment with letrozole can reduce breast cancer recurrence risk 3
All Day Comfort for the Upper Body...
Designed for special procedures, this Wrap-Around apron has .50mm Pb in the front and .25mm Pb in the back. The velcro fasteners are adjustable to provide the most comfortable fit....
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
This aron protects at 0.5 mm Pb equivalency and is 20% lighter than our Standard Back-Aid Apron - yet it contains no lead products that can be harmful to the environment!...
Medicine Products: